GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DNA Chip Research Inc (TSE:2397) » Definitions » Capex-to-Operating-Cash-Flow

DNA Chip Research (TSE:2397) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is DNA Chip Research Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

DNA Chip Research's Capital Expenditure for the three months ended in Dec. 2023 was 円0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was 円0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


DNA Chip Research Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for DNA Chip Research's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DNA Chip Research Capex-to-Operating-Cash-Flow Chart

DNA Chip Research Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DNA Chip Research Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DNA Chip Research's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, DNA Chip Research's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DNA Chip Research's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, DNA Chip Research's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where DNA Chip Research's Capex-to-Operating-Cash-Flow falls into.



DNA Chip Research Capex-to-Operating-Cash-Flow Calculation

DNA Chip Research's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-126.128) / -336.713
=N/A

DNA Chip Research's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DNA Chip Research  (TSE:2397) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


DNA Chip Research Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of DNA Chip Research's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


DNA Chip Research (TSE:2397) Business Description

Traded in Other Exchanges
N/A
Address
1-1-43 Suehirocho, Tsurumi-ku, Yokohama, JPN
DNA Chip Research Inc is specializing in the development of DNA microarrays. Its major business is focused on research and development, contract research service, and diagnostic support service. The company provides a wide variety of analytical services, from DNA chips to state-of-the-art next-generation sequencing. In addition, it provides consultation on experimental planning, sample preparation, statistical analysis, and manuscript preparation, catering to researchers' needs and requirements.

DNA Chip Research (TSE:2397) Headlines

No Headlines